1PASSWORD
4.6.2024 07:01:32 CEST | Business Wire | Press release
1Password, a leader in identity security, today announced significant business momentum across Europe, the Middle East, and Africa (EMEA). With a strategic focus on the region, 1Password is expanding its workforce, launching products tailored to the EMEA market, and securing over 35% of Europe’s Top 100 companies. Today, over one-third of 1Password’s B2B customers are based in EMEA.
The majority (68%) of security breaches are still caused by a human element resulting in compromised credentials, and the company recently launched 1Password Extended Access Management (XAM), an industry-first solution designed to secure every login to every app from every device, addressing the modern workforce’s need for even more seamless and secure access. Now available in the EMEA region, this solution protects users' privacy and gives businesses strong security across managed and unmanaged applications and devices, while offering visibility and insights to help them meet resilience, compliance, and audit goals. As a leading enterprise password manager, 1Password enhances identity security by providing businesses with secure access to their most sensitive information, such as login credentials and SSH keys, actionable insights to address vulnerabilities, and seamless integration with existing security infrastructure.
1Password recently hired Oliver Cheal as Vice President, EMEA. In this role, he will oversee the company’s EMEA-based teams that are focused on designing, developing, selling, and supporting 1Password’s identity and access management solutions for customers in the region. Cheal was most recently at Cisco and Duo Security and his background is in transforming cybersecurity businesses by leading organizational change and building out the go-to-market function. With more than 100 employees in EMEA, 1Password is actively investing in its EMEA workforce, with plans to open positions across sales, marketing, customer success, and partnerships in the UK, Netherlands, and Germany.
“I am thrilled to join 1Password at such a pivotal time and grow our EMEA team to better serve our customers across the region,” said Oliver Cheal, VP of EMEA. “With 1Password Extended Access Management, we're revolutionizing access management by bridging the gaps left by traditional IAM solutions. With its seamless integration and user-friendly design, we are able to empower IT and security teams with unparalleled visibility and control, ensuring their employees can safely use the tools they need, whether working remotely or in the office.”
Earlier this year, the company launched the 1Password Global Partner Program and the 1Password® Enterprise Password Manager - MSP Edition in beta to provide resellers, distributors, and Managed Service Providers (MSPs) with the tools and resources they need to help their customers become more secure. Key strategic partners in EMEA include Amazon Web Services (AWS), Arrow Electronics, Insight Enterprises, Tap.De, and SVA.
“Watching 1Password's expansion into EMEA is incredibly exciting. Their growth and vision have always perfectly aligned with ours, and we are thrilled to be part of this journey, supporting their success every step of the way. By addressing critical security gaps with their new Extended Access Management (XAM) solution, 1Password is pioneering a new category in cybersecurity that ensures comprehensive protection across the modern, hybrid work environment and we are excited to be their partner,” said Ikramul Khaled, the Group Head of Vendor Alliances at QBS Technology Group.
For more information about 1Password, visit our website here.
About 1Password
Trusted by over 150,000 businesses and millions of consumers, 1Password offers identity security and access management solutions built for the way people work and live today. 1Password is on a mission to eliminate the conflict between security and productivity while securing every sign-in for every app on every device. As the provider of the most-used enterprise password manager, 1Password continues to innovate on its strong foundation to offer security solutions relied upon by companies of all sizes, including Associated Press, Salesforce, GitLab, Under Armour, and Intercom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603036115/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom